argenex (NASDAQ:ARGX - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $720.00 price target on the stock. HC Wainwright's target price points to a potential upside of 30.62% from the stock's current price.
Several other equities analysts have also weighed in on the stock. Citigroup restated a "buy" rating on shares of argenex in a research report on Wednesday, May 21st. Guggenheim decreased their price target on argenex from $1,100.00 to $1,065.00 and set a "buy" rating for the company in a research note on Friday, May 9th. JMP Securities set a $699.00 target price on shares of argenex in a research note on Wednesday, May 14th. Baird R W raised argenex from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 13th. Finally, Sanford C. Bernstein upgraded shares of argenex from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. One analyst has rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $729.93.
Check Out Our Latest Research Report on argenex
argenex Stock Performance
Shares of NASDAQ ARGX opened at $551.22 on Tuesday. The firm has a market cap of $33.66 billion, a P/E ratio of 34.00, a price-to-earnings-growth ratio of 1.01 and a beta of 0.39. The firm's 50 day moving average price is $580.69 and its 200 day moving average price is $606.71. argenex has a 1 year low of $428.97 and a 1 year high of $678.21.
argenex (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. argenex had a net margin of 40.20% and a return on equity of 16.15%. The firm had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $748.34 million. As a group, equities analysts predict that argenex will post 3.13 EPS for the current year.
Institutional Investors Weigh In On argenex
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC raised its position in shares of argenex by 17.2% in the 4th quarter. FMR LLC now owns 5,618,222 shares of the company's stock worth $3,455,207,000 after buying an additional 824,750 shares during the period. Capital World Investors raised its holdings in shares of argenex by 5.1% in the 4th quarter. Capital World Investors now owns 1,786,936 shares of the company's stock worth $1,099,002,000 after purchasing an additional 86,687 shares during the period. RTW Investments LP lifted its stake in shares of argenex by 2.9% in the 4th quarter. RTW Investments LP now owns 673,497 shares of the company's stock valued at $414,201,000 after purchasing an additional 19,067 shares in the last quarter. Clearbridge Investments LLC increased its position in shares of argenex by 6.8% in the fourth quarter. Clearbridge Investments LLC now owns 629,828 shares of the company's stock worth $387,344,000 after acquiring an additional 40,330 shares in the last quarter. Finally, Lord Abbett & CO. LLC raised its position in argenex by 33.2% in the first quarter. Lord Abbett & CO. LLC now owns 274,700 shares of the company's stock valued at $162,585,000 after purchasing an additional 68,498 shares during the period. Hedge funds and other institutional investors own 60.32% of the company's stock.
argenex Company Profile
(
Get Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider argenex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenex wasn't on the list.
While argenex currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
